London-based startup Punto Health has raised €2.3m in seed funding to scale its AI dementia care platform across the UK and Spain.
The seed round was co-led by Shilling VC and Plus Partners, with participation from Exceptional Ventures, Heartfelt, Fondo Bolsa Social and ABAC Nest.
Punto Health says the investment will accelerate product development and commercial expansion.
Founded in 2023 by engineers Anna Muñoz-Farré and Jack Eckersley, Punto Health develops AI tools for early detection and personalised support in dementia and cognitive decline.
Its multilingual platform connects patients, carers and clinicians across three products.
Anna Muñoz-Farré, chief executive and co-founder, said: “Dementia is never just one person’s disease. It affects entire families, and carers often carry an enormous invisible burden.
“We are building technology that turns a reactive, crisis-driven system into proactive, personalised support that fits into people’s real lives.”
PuntoTest is an AI, speech-based digital test for assessing cognitive impairment.
PuntoCare is a companion app for patients, carers and active older people with care plans, cognitive exercises, nutrition advice, symptom tracking and activity guidance.
PuntoClinic is a clinician dashboard that aggregates patient-reported outcomes and biomarker data (objective biological measures) to support decisions.
The platform is co-designed and clinically validated with Ace Alzheimer Centre Barcelona.
According to the company, PuntoTest has been used in a rapid screening programme across ten pharmacies in Barcelona, involving more than 1,500 participants aged 50 and above.
The platform is also being piloted at North London NHS FT, NHS Oxleas FT, Hospital del Mar in Barcelona and Hospital General de Granollers.
Punto Health says it now supports more than 200 users, aged 60 to 90, who have completed over 30,000 activities, with more than two-thirds reporting improved confidence in managing daily routines.
